BLACKROCK TECH & PRIV EQTY (BTX) Stock News
NYSE:BTX - New York Stock Exchange, Inc. - US09260Q1085 - Currency: USD
BTX Latest News, Press Relases and Analysis
Certain BlackRock Closed-End Funds Announce Estimated Sources of Distributions
BlackRock Announces Shareholder Approval of Strategy Changes to the BlackRock Technology and Private Equity Term Trust (BTX)
Brooklyn ImmunoTherapeutics Shares Tick lower After Data From Head and Neck Cancer Study
Distribution Dates and Amounts Announced for Certain BlackRock Closed-End Funds
Certain BlackRock Closed-End Funds Announce Estimated Sources of Distributions
Certain BlackRock Closed-End Funds Announce Renewal of Discount Management Programs
Distribution Dates and Amounts Announced for Certain BlackRock Closed-End Funds
Certain BlackRock Closed-End Funds Announce Estimated Sources of Distributions
Brooklyn ImmunoTherapeutics Announces Name Change to Eterna Therapeutics and Provides Corporate Updates
New name reflects Company focus on leveraging exclusively in-licensed foundational mRNA cell engineering patent portfolio The Eterna corporate mission is...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning, investor! It's time to start the day with a breakdown of the biggest pre-market stock movers for Tuesday morning!
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers SenesTech (NASDAQ:SNES) stock rose 28.0% to $0.64 during Thursday's after-market session. The market value of their outstanding shares is at $7.8 million.
Brooklyn ImmunoTherapeutics Announces Results of Phase 2 Study of IRX-2 in Head and Neck Cancer
SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn” or the “Company”) today announces results from...
Brooklyn ImmunoTherapeutics Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
SAN DIEGO, June 17, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn” or the “Company”), a biopharmaceutical company...
Brooklyn ImmunoTherapeutics Announces Board Changes
SAN DIEGO, June 07, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn” or the “Company”), a biopharmaceutical company...
Brooklyn ImmunoTherapeutics Announces Changes to Executive Management: Matt Angel, Ph.D. Appointed Interim Chief Executive Officer and President, Andrew Jackson Appointed Chief Financial Officer Postpones 2022 Annual Meeting
SAN DIEGO, May 31, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn” or the “Company”), a biopharmaceutical company...
Brooklyn ImmunoTherapeutics Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Quarterly Report on Form 10-Q
SAN DIEGO, May 27, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring...
Brooklyn ImmunoTherapeutics Announces Establishment of New Research and Development Facility for Advancement of Engineered Cellular Medicines
Company has expanded team with scientific hires who hold research expertise in stem cells, synthetic RNA, nanoparticle delivery systems and immunology...
Brooklyn ImmunoTherapeutics Announces Fourth Quarter and Full Year 2021 Financial Results
SAN DIEGO, April 15, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn”), a biopharmaceutical company focused on...
Brooklyn ImmunoTherapeutics Announces Closing of $12 Million Private Placement
NEW YORK, March 09, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on...
Brooklyn ImmunoTherapeutics Welcomes Erin S. Enright and Heather B. Redman to Its Board of Directors
NEW YORK, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on...
Brooklyn ImmunoTherapeutics Provides Update on Regenerative Medicine Intellectual Property Portfolio
NEW YORK, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on...
Brooklyn ImmunoTherapeutics Added to ICE Biotechnology Index
NEW YORK, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on...
Brooklyn ImmunoTherapeutics Named to Nasdaq Biotechnology Index
NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on...
Brooklyn ImmunoTherapeutics to Present at Two Upcoming December Conferences
NEW YORK, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on...